A Phase 3 interventional study of Lomitapide in Homozygous Familial Hypercholesterolaemia (HoFH), sponsored by Amryt Pharma. Completed at 12 sites in 6 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Amryt Pharma (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) comprising of the following phases:
Lomitapide has been approved for use in adult patients with HoFH in the European Union (EU) and European Economic Area (EEA), United States of America (USA), Israel, Argentina, Canada, Colombia, and Japan. This study is designed to determine if lomitapide is effective and can be safely administered to paediatric patients with HoFH. If the efficacy and safety so far observed in adults is confirmed in paediatric patients, the potential exists to significantly lower low-density lipoprotein cholesterol (LDL-C) levels in paediatric patients with HoFH. Furthermore, the lower LDL-C levels may reduce atherosclerosis progression and would be expected to benefit these paediatric patients with HoFH.
A single arm, non comparator design has been selected due to the rarity of the disease and because the evaluation of safety variables such as growth and sexual maturation requires longer term observation than would be feasible in the context of a placebo controlled study.
To mitigate the disadvantages of a single arm design, the study includes a Run in Period of at least 6 weeks during which current lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) will be stabilised to establish baseline levels allowing each patient to serve as his/her own control. Patients will also remain on stable LLT (including LA, when applicable) during the Efficacy Phase of the study through Week 24±3 days.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 46 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →Amryt Pharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female patients aged 5 to ≤17 years with HoFH as defined by any of the following criteria recommended by the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) (Cuchel, Bruckert et al. 2014):
Baseline LDL C on LLT (maximum concentration [Cmax] immediately prior to LA, if applicable)
Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions, particularly that
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lomitapide dosing commenced with 2mg at week 1 for 8 Weeks,then increased to 5mg at Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.
Drug: Lomitapide
Lomitapide dosing commenced with 2mg at week 1 for 4 Weeks, then increased to 5mg at Week 4±3 days, 10 mg at Week 8±3 days, 20mg at Week 12±3 days to the maximum allowable dose of 40mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.
Drug: Lomitapide
Lomitapide dosing commenced with 5mg at week 1 for 4 Weeks, then increased to 10mg at Week 4±3 days, 20 mg at Week 8±3 days, 40mg at Week 12±3 days to the maximum allowable dose of 60mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.
Drug: Lomitapide
2mg,5mg, 10mg and 20mg capsules
Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline
To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 24
Efficacy Endpoint: Percent Change From Baseline at Week 24 for Various Lipid Parameters
To evaluate the efficacy of lomitapide, as defined by the percent change of the following lipid parameters at the maximum tolerated dose (MTD): * Non-high-density lipoprotein cholesterol (Non-HDL-C) * Total cholesterol (TC) * Very-low-density lipoprotein cholesterol (VLDL-C) * Apolipoprotein B (Apo B) * TG (Triglycerides)
Time frame: Baseline through Week 24
Efficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a)
To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 24
Percent Change From Baseline at All Other Time Points Through Week 104 for LDL-C
To evaluate the efficacy of lomitapide, as defined by the percent change in LDL-C at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for Non-HDL-C
To evaluate the efficacy of lomitapide, as defined by the percent change in Non-HDL-C at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for TC
To evaluate the efficacy of lomitapide, as defined by the percent change in TC at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for VLDL-C
To evaluate the efficacy of lomitapide, as defined by the percent change in VLDL-C at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for Apo B
To evaluate the efficacy of lomitapide, as defined by the percent change in apo B at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for TG
To evaluate the efficacy of lomitapide, as defined by the percent change in TG at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change From Baseline at All Other Time Points Through Week 104 for Lipoprotein(a) (Lp(a))
To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change in TC/HDL-C Ratio From Baseline at All Other Time Points to Week 104
To evaluate the efficacy of lomitapide, as defined by the percent change in TC/HDL-C ratio at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104
Percent Change in HDL-C From Baseline at All Other Time Points to Week 104
To evaluate the efficacy of lomitapide, as defined by the percent change in HDL-C at the maximum tolerated dose (MTD)
Time frame: Baseline through Week 104 week
Change in LLT From Week 28 Through Week 104
To evaluate the efficacy of lomitapide, as defined by the change in background lipid lowering therapy
Time frame: Week 28 through Week 104
Change in LA From Week 28 Through Week 104
To evaluate the efficacy of lomitapide, as defined by the change in lipoprotein apheresis
Time frame: Week 28 through Week 104
Number and Percentage of Patients Achieving European Atherosclerosis Society (EAS) Recommended Target (2013) of LDL-C at Any Timepoint Between Baseline and Week 24
To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C
Time frame: Baseline through Week 24
Number and Percentage of Patients Achieving EAS Recommended Target (2013) of LDL-C at Any Time in the Study
To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C
Time frame: Baseline through Week 104
Percent Change of Body Mass Index (BMI)
To evaluate the efficacy of lomitapide, as defined by the percent change of BMI
Time frame: Baseline through Week 104
Lipid Accumulation in the Liver Over Time Measured by Nuclear Magnetic Resonance (NMR) at Baseline and at Week 24, Week 56 and at Week 104
To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by nuclear magnetic resonance (NMR)
Time frame: Baseline through Week 104
Lipid Accumulation in the Liver Over Time Measured by Ultrasound at Baseline and at Week 24, Week 56 and at Week 104
To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by ultrasound
Time frame: Baseline through Week 104
Male and female subjects aged 5 to ≤17 years with HoFH were enrolled in the trial at 12 study centres in various countries (3 in Germany, 1 in Israel, 2 in Italy, 2 in Saudi Arabia, 3 in Spain and 1 in Tunisia). The first patient first visit was 14 Dec 2020 and the last patient last visit was 06 Jun 2024.
| Milestone | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| Started | 21 | 25 |
| Completed | 21 | 25 |
| Not completed | 0 | 0 |
| Milestone | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| Started | 21 | 25 |
| Completed | 20 | 23 |
| Not completed | 1 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Milestone | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| Started | 20 | 23 |
| Completed | 20 | 21 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 |
| Milestone | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| Started | 20 | 21 |
| Completed | 20 | 19 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Aes and none compliance | 0 | 1 |
To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline | -53.910 ± 25.8287 | -56.529 ± 26.5401 | -51.633 ± 25.5658 |
To evaluate the efficacy of lomitapide, as defined by the percent change of the following lipid parameters at the maximum tolerated dose (MTD): * Non-high-density lipoprotein cholesterol (Non-HDL-C) * Total cholesterol (TC) * Very-low-density lipoprotein cholesterol (VLDL-C) * Apolipoprotein B (Apo B) * TG (Triglycerides)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Non-HDL-C | -54.185 ± 25.0256 | -56.655 ± 25.9804 | -52.038 ± 24.5423 |
| TC | -50.176 ± 24.5397 | -52.883 ± 25.6260 | -47.822 ± 23.8756 |
| VLDL-C | -49.678 ± 31.6126 | -53.030 ± 28.0698 | -46.763 ± 34.7606 |
| Apo B | -53.1 ± 24.76 | -56.2 ± 24.45 | -50.4 ± 25.26 |
| TG | -49.28 ± 31.7290 | -52.292 ± 27.8956 | -46.674 ± 35.1359 |
To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Efficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a) | -26.757 ± 32.5675 | -17.248 ± 36.4246 | -36.996 ± 25.3314 |
To evaluate the efficacy of lomitapide, as defined by the percent change in LDL-C at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | -1.962 ± 20.7168 | -5.936 ± 10.8438 | 1.651 ± 26.5109 |
| Week 8 | -6.798 ± 19.1524 | -2.037 ± 11.8697 | -11.058 ± 23.3978 |
| Week 12 | -16.638 ± 23.1978 | -11.742 ± 16.1686 | -21.289 ± 27.9618 |
| Week 16 | -36.458 ± 17.9894 | -32.971 ± 14.6467 | -40.163 ± 20.8120 |
| Week 20 | -50.730 ± 24.8321 | -49.906 ± 25.1366 | -51.476 ± 25.1505 |
| Week 24 | -54.602 ± 26.4557 | -55.825 ± 27.9112 | -53.554 ± 25.7903 |
| Week 28 | -55.518 ± 28.5714 | -57.929 ± 29.0704 | -53.108 ± 28.6469 |
| Week 32 | -52.126 ± 28.7496 | -55.561 ± 29.7938 | -48.086 ± 27.8122 |
| Week 36 | -39.823 ± 32.6612 | -45.072 ± 32.4809 | -34.574 ± 32.9076 |
| Week 40 | -49.427 ± 29.5830 | -52.511 ± 27.4375 | -46.637 ± 31.8088 |
| Week 44 | -44.312 ± 30.3775 | -53.502 ± 25.8673 | -35.122 ± 32.3611 |
| Week 48 | -45.315 ± 29.6526 | -53.965 ± 23.2741 | -37.963 ± 32.9544 |
| Week 52 | -44.583 ± 32.8128 | -52.956 ± 25.8671 | -35.718 ± 37.6118 |
| Week 56 | -45.994 ± 34.3631 | -57.616 ± 28.1958 | -33.761 ± 36.6832 |
| Week 68 | -40.831 ± 37.3821 | -52.220 ± 24.9512 | -31.151 ± 43.6898 |
| Week 80 | -42.319 ± 34.9400 | -49.410 ± 28.8677 | -35.227 ± 39.6221 |
| Week 92 | -37.199 ± 39.6625 | -41.059 ± 33.6178 | -32.910 ± 46.0836 |
| Week 104 | -40.159 ± 30.5026 | -43.168 ± 25.4634 | -37.150 ± 35.3743 |
To evaluate the efficacy of lomitapide, as defined by the percent change in Non-HDL-C at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | -1.765 ± 21.1682 | -5.950 ± 10.5881 | 2.039 ± 27.2319 |
| Week 8 | -6.745 ± 18.6776 | -1.938 ± 12.1118 | -11.045 ± 22.5075 |
| Week 12 | -16.497 ± 22.9850 | -12.039 ± 15.5376 | -20.733 ± 28.0917 |
| Week 16 | -36.610 ± 17.4339 | -33.214 ± 14.6890 | -40.218 ± 19.7812 |
| Week 20 | -50.928 ± 24.3958 | -50.150 ± 24.7267 | -51.632 ± 24.6817 |
| Week 24 | -55.033 ± 25.4297 | -56.006 ± 27.3439 | -54.200 ± 24.3220 |
| Week 28 | -55.984 ± 27.5559 | -58.201 ± 28.4121 | -53.768 ± 27.2620 |
| Week 32 | -52.629 ± 27.8748 | -55.742 ± 29.1688 | -49.171 ± 26.7611 |
| Week 36 | -40.574 ± 31.4293 | -45.464 ± 31.6491 | -35.685 ± 31.3277 |
| Week 40 | -50.013 ± 28.4878 | -52.837 ± 26.6409 | -47.458 ± 30.4850 |
| Week 44 | -44.702 ± 29.8885 | -53.685 ± 25.3674 | -35.720 ± 31.9421 |
| Week 48 | -46.770 ± 29.3974 | -55.873 ± 23.6964 | -38.577 ± 32.1148 |
| Week 52 | -45.222 ± 31.9577 | -53.190 ± 25.4004 | -36.785 ± 36.5745 |
| Week 56 | -46.558 ± 33.4734 | -57.724 ± 27.7033 | -34.805 ± 35.6510 |
| Week 68 | -41.576 ± 36.0854 | -52.331 ± 24.4942 | -32.433 ± 42.0777 |
| Week 80 | -42.388 ± 34.3439 | -49.605 ± 28.2105 | -35.171 ± 38.9712 |
| Week 92 | -37.755 ± 38.4243 | -41.420 ± 32.7680 | -33.682 ± 44.4970 |
| Week 104 | -40.511 ± 30.1102 | -43.555 ± 24.5843 | -37.468 ± 35.2966 |
To evaluate the efficacy of lomitapide, as defined by the percent change in TC at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | -2.057 ± 19.3772 | -5.487 ± 10.2352 | 1.062 ± 24.8373 |
| Week 8 | -6.970 ± 17.6904 | -3.092 ± 13.2354 | -10.643 ± 20.7648 |
| Week 12 | -15.961 ± 21.4313 | -12.881 ± 15.4304 | -19.041 ± 26.1667 |
| Week 16 | -33.976 ± 15.7159 | -30.986 ± 14.0719 | -37.154 ± 17.1693 |
| Week 20 | -48.177 ± 23.2987 | -48.524 ± 23.7013 | -47.847 ± 23.4897 |
| Week 24 | -50.922 ± 24.9738 | -52.132 ± 26.9234 | -49.885 ± 23.7998 |
| Week 28 | -51.998 ± 26.9668 | -54.806 ± 27.4139 | -49.190 ± 26.9564 |
| Week 32 | -48.945 ± 26.2375 | -52.642 ± 27.5342 | -44.838 ± 24.8402 |
| Week 36 | -40.643 ± 30.5125 | -45.656 ± 29.7175 | -35.365 ± 31.2402 |
| Week 40 | -45.402 ± 27.5358 | -46.997 ± 27.2264 | -43.882 ± 28.4123 |
| Week 44 | -41.443 ± 28.3745 | -50.186 ± 24.6881 | -32.699 ± 29.7008 |
| Week 48 | -44.164 ± 27.6987 | -53.422 ± 22.4426 | -35.369 ± 29.8353 |
| Week 52 | -42.764 ± 30.6617 | -51.169 ± 24.8422 | -33.371 ± 34.4186 |
| Week 56 | -43.234 ± 31.3599 | -54.109 ± 26.0580 | -31.787 ± 33.0105 |
| Week 68 | -39.672 ± 33.2025 | -49.108 ± 24.7124 | -30.236 ± 38.2710 |
| Week 80 | -40.291 ± 31.9119 | -48.031 ± 26.5964 | -32.143 ± 35.5890 |
| Week 92 | -34.946 ± 35.8485 | -38.474 ± 31.6123 | -31.025 ± 40.6102 |
| Week 104 | -36.017 ± 32.2354 | -42.430 ± 24.0856 | -29.605 ± 38.3282 |
To evaluate the efficacy of lomitapide, as defined by the percent change in VLDL-C at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 9.770 ± 42.2029 | 1.911 ± 30.6624 | 16.914 ± 50.1439 |
| Week 8 | 2.857 ± 34.5887 | 5.190 ± 35.0331 | 0.771 ± 35.0086 |
| Week 12 | -7.405 ± 48.8428 | -6.638 ± 54.7493 | -8.133 ± 43.9360 |
| Week 16 | -34.706 ± 31.6590 | -36.773 ± 23.3455 | -32.509 ± 39.3305 |
| Week 20 | -49.068 ± 25.6958 | -51.943 ± 26.4251 | -46.467 ± 25.3796 |
| Week 24 | -53.050 ± 27.2118 | -54.447 ± 27.8824 | -51.853 ± 27.2551 |
| Week 28 | -55.394 ± 25.0601 | -58.209 ± 24.3762 | -52.579 ± 26.0764 |
| Week 32 | -47.899 ± 55.7396 | -54.787 ± 28.1792 | -39.796 ± 76.9320 |
| Week 36 | -46.596 ± 25.9994 | -47.963 ± 24.7584 | -45.230 ± 27.8348 |
| Week 40 | -51.167 ± 26.7498 | -55.266 ± 21.3853 | -47.458 ± 30.8760 |
| Week 44 | -46.750 ± 33.3163 | -54.803 ± 19.0837 | -38.696 ± 42.1620 |
| Week 48 | -38.148 ± 50.6100 | -50.109 ± 35.8714 | -27.981 ± 59.4366 |
| Week 52 | -49.469 ± 30.0996 | -55.576 ± 20.3440 | -43.004 ± 37.4046 |
| Week 56 | -47.051 ± 32.7429 | -55.292 ± 28.1394 | -38.375 ± 35.6732 |
| Week 68 | -47.832 ± 30.6844 | -50.902 ± 21.1040 | -45.223 ± 37.3270 |
| Week 80 | -36.881 ± 44.5589 | -46.520 ± 29.3256 | -27.242 ± 55.0014 |
| Week 92 | -41.368 ± 31.7375 | -44.652 ± 23.2247 | -37.718 ± 39.5304 |
| Week 104 | -39.055 ± 40.2422 | -44.612 ± 26.8209 | -33.498 ± 50.5480 |
To evaluate the efficacy of lomitapide, as defined by the percent change in apo B at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 0.2 ± 18.99 | -0.5 ± 16.45 | 0.9 ± 21.41 |
| Week 8 | -6.5 ± 19.25 | -2.4 ± 16.63 | -10.3 ± 21.15 |
| Week 12 | -15.5 ± 21.91 | -10.3 ± 14.37 | -20.8 ± 26.84 |
| Week 16 | -36.1 ± 16.70 | -32.6 ± 14.52 | -39.7 ± 18.50 |
| Week 20 | -51.6 ± 24.21 | -52.1 ± 24.26 | -51.2 ± 24.76 |
| Week 24 | -54.0 ± 25.02 | -55.4 ± 25.73 | -52.7 ± 24.96 |
| Week 28 | -56.2 ± 26.17 | -59.2 ± 25.77 | -53.2 ± 26.91 |
| Week 32 | -52.0 ± 28.64 | -55.7 ± 27.78 | -47.8 ± 29.80 |
| Week 36 | -43.9 ± 30.91 | -47.4 ± 31.45 | -40.3 ± 30.74 |
| Week 40 | -48.9 ± 29.11 | -50.6 ± 27.92 | -47.3 ± 30.81 |
| Week 44 | -46.1 ± 28.75 | -53.5 ± 25.61 | -38.7 ± 30.42 |
| Week 48 | -48.6 ± 29.03 | -56.9 ± 24.99 | -40.7 ± 30.97 |
| Week 52 | -47.7 ± 30.16 | -55.4 ± 26.77 | -39.1 ± 32.14 |
| Week 56 | -47.1 ± 33.06 | -57.7 ± 28.41 | -35.9 ± 34.63 |
| Week 68 | -44.8 ± 33.99 | -53.9 ± 24.92 | -35.7 ± 39.71 |
| Week 80 | -47.1 ± 30.58 | -53.7 ± 25.96 | -40.0 ± 34.09 |
| Week 92 | -41.8 ± 35.12 | -45.5 ± 28.97 | -37.7 ± 41.39 |
| Week 104 | -44.6 ± 30.22 | -51.1 ± 22.42 | -38.1 ± 35.85 |
To evaluate the efficacy of lomitapide, as defined by the percent change in TG at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 9.387 ± 41.7233 | 1.699 ± 32.1342 | 16.376 ± 48.5494 |
| Week 8 | 2.649 ± 35.3115 | 5.577 ± 36.3036 | 0.029 ± 35.1807 |
| Week 12 | -7.258 ± 49.6990 | -6.133 ± 56.7548 | -8.327 ± 43.4273 |
| Week 16 | -34.970 ± 30.2259 | -37.161 ± 23.9242 | -32.643 ± 36.4318 |
| Week 20 | -48.989 ± 25.8872 | -51.346 ± 27.1808 | -46.856 ± 25.1360 |
| Week 24 | -52.878 ± 26.8475 | -53.866 ± 27.5741 | -52.031 ± 26.8624 |
| Week 28 | -55.639 ± 24.6317 | -57.852 ± 24.1398 | -53.426 ± 25.5749 |
| Week 32 | -48.697 ± 54.0396 | -54.381 ± 28.4810 | -42.380 ± 73.2737 |
| Week 36 | -46.823 ± 25.4762 | -48.286 ± 23.9243 | -45.361 ± 27.5563 |
| Week 40 | -51.612 ± 25.9533 | -55.105 ± 20.8662 | -48.451 ± 29.9921 |
| Week 44 | -47.065 ± 31.7596 | -54.885 ± 18.5911 | -39.245 ± 39.9507 |
| Week 48 | -39.769 ± 48.3307 | -51.803 ± 35.2601 | -28.939 ± 56.3536 |
| Week 52 | -49.415 ± 28.4096 | -55.142 ± 20.0234 | -43.352 ± 34.8302 |
| Week 56 | -47.707 ± 32.0150 | -55.648 ± 26.7620 | -39.349 ± 35.5528 |
| Week 68 | -48.471 ± 30.8061 | -51.253 ± 21.5583 | -46.107 ± 37.3356 |
| Week 80 | -38.312 ± 44.1074 | -47.765 ± 27.6927 | -28.860 ± 55.1679 |
| Week 92 | -41.549 ± 30.2027 | -45.140 ± 23.5731 | -37.558 ± 36.5005 |
| Week 104 | -39.739 ± 39.8597 | -45.352 ± 25.8574 | -34.126 ± 50.4118 |
To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 9.660 ± 63.5768 | 24.269 ± 84.1451 | -6.072 ± 23.8773 |
| Week 8 | 1.508 ± 46.1156 | 13.870 ± 54.0530 | -13.327 ± 30.7067 |
| Week 12 | 0.592 ± 32.5241 | 13.509 ± 36.2732 | -15.847 ± 17.2462 |
| Week 16 | -14.648 ± 26.3140 | -6.564 ± 29.3156 | -26.775 ± 15.7748 |
| Week 20 | -16.602 ± 47.9856 | -3.961 ± 58.6273 | -31.540 ± 26.7998 |
| Week 24 | -28.874 ± 33.5277 | -15.021 ± 38.1874 | -42.728 ± 21.9120 |
| Week 28 | -32.628 ± 32.4047 | -23.314 ± 36.5744 | -46.081 ± 20.1331 |
| Week 32 | -20.594 ± 50.1160 | -27.534 ± 46.6328 | -10.877 ± 55.6561 |
| Week 36 | -25.278 ± 32.4201 | -21.547 ± 36.2351 | -32.741 ± 23.6913 |
| Week 40 | -28.257 ± 34.6849 | -20.400 ± 39.7347 | -40.480 ± 21.6021 |
| Week 44 | -30.124 ± 34.9943 | -25.915 ± 38.3512 | -37.940 ± 28.7510 |
| Week 48 | -17.905 ± 38.3429 | -8.621 ± 43.0927 | -35.145 ± 20.2017 |
| Week 52 | -25.635 ± 42.3832 | -17.270 ± 47.3261 | -41.170 ± 27.8522 |
| Week 56 | -22.366 ± 34.5809 | -14.691 ± 33.9040 | -36.621 ± 33.5132 |
| Week 68 | -20.634 ± 42.9257 | -9.136 ± 47.0506 | -41.989 ± 24.2691 |
| Week 80 | -22.659 ± 42.2271 | -19.135 ± 48.3708 | -30.295 ± 26.4884 |
| Week 92 | -22.235 ± 41.1508 | -16.468 ± 44.0841 | -37.229 ± 31.2661 |
| Week 104 | -29.064 ± 34.5930 | -24.776 ± 37.6534 | -40.212 ± 24.8480 |
To evaluate the efficacy of lomitapide, as defined by the percent change in TC/HDL-C ratio at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 0.108 ± 27.5756 | -10.581 ± 14.9489 | 9.825 ± 32.7827 |
| Week 8 | -5.292 ± 29.1737 | -7.941 ± 22.3051 | -2.921 ± 34.6428 |
| Week 12 | -14.501 ± 27.7248 | -13.695 ± 24.7560 | -15.266 ± 30.9105 |
| Week 16 | -33.384 ± 25.8765 | -38.768 ± 21.4831 | -27.664 ± 29.4691 |
| Week 20 | -45.689 ± 27.0372 | -51.512 ± 24.7014 | -40.421 ± 28.5476 |
| Week 24 | -52.155 ± 25.1906 | -60.174 ± 23.4381 | -45.281 ± 25.1244 |
| Week 28 | -50.986 ± 31.0715 | -59.358 ± 27.4688 | -42.614 ± 32.8937 |
| Week 32 | -48.651 ± 35.4572 | -55.596 ± 32.8921 | -40.934 ± 37.5141 |
| Week 36 | -35.860 ± 35.4801 | -45.043 ± 34.3337 | -26.677 ± 35.1331 |
| Week 40 | -43.976 ± 36.8573 | -56.120 ± 26.2125 | -32.988 ± 41.9967 |
| Week 44 | -40.395 ± 38.1876 | -54.594 ± 28.2165 | -26.197 ± 42.1040 |
| Week 48 | -41.720 ± 36.2674 | -54.921 ± 27.6549 | -29.839 ± 39.5405 |
| Week 52 | -43.496 ± 38.2302 | -57.568 ± 26.0987 | -28.596 ± 43.8568 |
| Week 56 | -39.188 ± 55.5616 | -57.116 ± 31.2556 | -20.317 ± 68.9419 |
| Week 68 | -36.874 ± 41.9020 | -54.241 ± 26.5277 | -22.111 ± 47.2744 |
| Week 80 | -39.189 ± 37.9268 | -49.165 ± 33.2083 | -29.213 ± 40.5453 |
| Week 92 | -37.274 ± 41.0451 | -47.527 ± 33.5384 | -25.882 ± 46.3515 |
| Week 104 | -39.358 ± 34.3438 | -48.484 ± 25.6330 | -30.233 ± 39.9837 |
To evaluate the efficacy of lomitapide, as defined by the percent change in HDL-C at the maximum tolerated dose (MTD)
| Percent change from Baseline | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Week 4 | 1.428 ± 19.6280 | 7.659 ± 16.3760 | -4.236 ± 20.9511 |
| Week 8 | 4.482 ± 26.0635 | 12.855 ± 29.0476 | -3.010 ± 21.1047 |
| Week 12 | 4.912 ± 29.1215 | 8.692 ± 27.6073 | 1.322 ± 30.7607 |
| Week 16 | 8.059 ± 31.4604 | 19.392 ± 24.6238 | -3.984 ± 34.1243 |
| Week 20 | 6.186 ± 33.3664 | 17.873 ± 30.1872 | -4.387 ± 33.2219 |
| Week 24 | 11.412 ± 33.0044 | 24.967 ± 28.3089 | -0.208 ± 32.8835 |
| Week 28 | 11.154 ± 36.3133 | 19.883 ± 27.9809 | 2.425 ± 42.0330 |
| Week 32 | 15.137 ± 33.9304 | 19.607 ± 31.2092 | 10.171 ± 36.9795 |
| Week 36 | 8.537 ± 30.2218 | 14.424 ± 29.7110 | 2.651 ± 30.4028 |
| Week 40 | 10.043 ± 35.0097 | 25.145 ± 32.0096 | -3.620 ± 32.4844 |
| Week 44 | 12.765 ± 33.2136 | 22.486 ± 34.6933 | 3.044 ± 29.3561 |
| Week 48 | 13.602 ± 37.5732 | 25.097 ± 42.3692 | 3.256 ± 30.0858 |
| Week 52 | 18.032 ± 35.1079 | 31.674 ± 35.7852 | 3.587 ± 28.7665 |
| Week 56 | 11.528 ± 29.1750 | 21.636 ± 31.0975 | 0.887 ± 23.3045 |
| Week 68 | 9.557 ± 30.6616 | 21.183 ± 29.0036 | -0.326 ± 29.1404 |
| Week 80 | 11.606 ± 30.8242 | 17.203 ± 31.1788 | 6.010 ± 30.2457 |
| Week 92 | 17.320 ± 33.0024 | 29.691 ± 32.6733 | 3.574 ± 28.2358 |
| Week 104 | 16.109 ± 37.2987 | 26.224 ± 38.9780 | 5.994 ± 33.6550 |
To evaluate the efficacy of lomitapide, as defined by the change in background lipid lowering therapy
| Participants | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Reduction due to low LDL-C | 2 | 1 | 1 |
| Discontinuation due to lomitapide increase | 1 | 1 | 0 |
| Discontinuation due to other reason | 2 | 1 | 1 |
| Increase due to high LDL-C | 3 | 3 | 0 |
| Increase due to other reason | 1 | 1 | 0 |
To evaluate the efficacy of lomitapide, as defined by the change in lipoprotein apheresis
| Participants | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| Reduction due to Adverse Event (AE) | 1 | 1 | 0 |
| Reduction due to low LDL-C | 3 | 1 | 2 |
| Reduction due to other reason | 4 | 3 | 1 |
| Discontinuation due to low LDL-C | 1 | 1 | 0 |
| Discontinuation due to other reason | 1 | 1 | 0 |
To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C
| Participants | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| <135 mg/dL - anytime up to Week 24 | 18 | 7 | 11 |
| <115 mg/dL - anytime up to Week 24 | 16 | 5 | 11 |
| <110 mg/dL - anytime up to Week 24 | 14 | 4 | 10 |
To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C
| Participants | All Age Groups | Age 5-10 Years | Age 11-17 Years |
|---|---|---|---|
| <135 mg/dL - anytime up to week 104 | 23 | 10 | 13 |
| <115 mg/dL - anytime up to week 104 | 20 | 7 | 13 |
| <110 mg/dL - anytime up to week 104 | 19 | 6 | 13 |
To evaluate the efficacy of lomitapide, as defined by the percent change of BMI
| Percent change from Baseline | All Age Groups |
|---|---|
| Week 4 | -1.06 ± 3.466 |
| Week 8 | -1.32 ± 3.954 |
| Week 12 | -2.36 ± 4.768 |
| Week 16 | -2.96 ± 5.288 |
| Week 20 | -4.21 ± 5.708 |
| Week 24 | -5.04 ± 5.997 |
| Week 28 | -4.13 ± 6.427 |
| Week 32 | -3.60 ± 7.145 |
| Week 36 | -3.92 ± 7.949 |
| Week 40 | -3.78 ± 8.293 |
| Week 44 | -3.71 ± 10.406 |
| Week 48 | -3.92 ± 10.420 |
| Week 52 | -3.21 ± 10.738 |
| Week 56 | -2.90 ± 11.520 |
| Week 68 | -3.00 ± 12.103 |
| Week 80 | -1.90 ± 12.665 |
| Week 92 | -1.00 ± 14.108 |
| Week 104 | -0.11 ± 13.718 |
To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by nuclear magnetic resonance (NMR)
| Participants | 5-10 Years | 11-17 Years |
|---|---|---|
| Baseline - ≤10% liver fat | 2 | 16 |
| Baseline - >10% and ≤20% liver fat | 0 | 1 |
| Baseline - >20% liver fat | 0 | 0 |
| Week 24 - ≤10% liver fat | 1 | 12 |
| Week 24 - >10% and ≤20% liver fat | 1 | 2 |
| Week 24 - >20% liver fat | 0 | 1 |
| Week 24 - No result | 2 | 4 |
| Week 56 - ≤10% liver fat | 0 | 9 |
| Week 56 - >10% and ≤20% liver fat | 1 | 4 |
| Week 56 - >20% liver fat | 0 | 0 |
| Week 56 - No result | 2 | 5 |
| Week 104/EoT - ≤10% liver fat | 3 | 11 |
| Week 104/EoT - >10% and ≤20% liver fat | 1 | 4 |
| Week 104/EoT - >20% liver fat | 0 | 0 |
To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by ultrasound
| Participants | 5-10 Years | 11-17 Years |
|---|---|---|
| Baseline - ≤10% liver fat | 17 | 2 |
| Baseline - >10% and ≤20% liver fat | 0 | 0 |
| Baseline - >20% liver fat | 0 | 0 |
| Week 24 - ≤10% liver fat | 15 | 2 |
| Week 24 - >10% and ≤20% liver fat | 0 | 0 |
| Week 24 - >20% liver fat | 0 | 0 |
| Week 24 - No result | 0 | 0 |
| Week 56 - ≤10% liver fat | 15 | 2 |
| Week 56 - >10% and ≤20% liver fat | 1 | 0 |
| Week 56 - >20% liver fat | 0 | 0 |
| Week 56 - No result | 0 | 0 |
| Week 104/EoT - ≤10% liver fat | 15 | 0 |
| Week 104/EoT - >10% and ≤20% liver fat | 0 | 1 |
| Week 104/EoT - >20% liver fat | 0 | 0 |
Collected over AEs were monitored throughout the study from the time of informed consent through Week 108.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age 5-10 Years | 1/20 (5%) | 4/20 (20%) | 19/20 (95%) |
| Age 11-17 Years | 1/23 (4.3%) | 7/23 (30.4%) | 23/23 (100%) |
| Event | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| Vascular device occlusionGeneral disorders | 2/20 | 0/23 |
| Vascular device infectionInfections and infestations | 0/20 | 2/23 |
| Transaminases increasedInvestigations | 1/20 | 0/23 |
| CataractEye disorders | 1/20 | 0/23 |
| AppendicitisInfections and infestations | 1/20 | 0/23 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 0/20 | 1/23 |
| Shunt occlusionInjury, poisoning and procedural complications | 0/20 | 1/23 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/20 | 1/23 |
| Aortic arteriosclerosisVascular disorders | 0/20 | 1/23 |
| Aortic valve disease mixedCardiac disorders | 0/20 | 1/23 |
| Event | Age 5-10 Years | Age 11-17 Years |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/20 | 13/23 |
| PyrexiaGeneral disorders | 10/20 | 4/23 |
| VomitingGastrointestinal disorders | 10/20 | 2/23 |
| Abdominal painGastrointestinal disorders | 8/20 | 11/23 |
| Alanine aminotransferase increasedInvestigations | 9/20 | 8/23 |
| Aspartate aminotransferase increasedInvestigations | 7/20 | 8/23 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/20 | 1/23 |
| AnaemiaBlood and lymphatic system disorders | 3/20 | 5/23 |
| COVID-19Infections and infestations | 4/20 | 5/23 |
| Blood creatine phosphokinase increasedInvestigations | 4/20 | 2/23 |
Baseline data shown are for participants who completed the baseline visit.
| Age, Categorical(Participants) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| <=18 years | 20 | 23 | 43 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| Mean | 7.0 ± 1.54 | 14.0 ± 1.97 | 10.7 ± 3.99 |
| Sex: Female, Male(Participants) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| Female | 10 | 14 | 24 |
| Male | 10 | 9 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 19 | 23 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 19 | 23 | 42 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| Saudi Arabia | 3 | 10 | 13 |
| Italy | 5 | 2 | 7 |
| Israel | 3 | 0 | 3 |
| Tunisia | 5 | 1 | 6 |
| Germany | 1 | 6 | 7 |
| Spain | 3 | 4 | 7 |
| Body mass index(kg/m2) | Age 5-10 Years | Age 11-17 Years | Total |
|---|---|---|---|
| Mean | 15.78 ± 3.338 | 21.52 ± 4.840 | 18.85 ± 5.071 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Oct 2022, 22 months.
Results were first posted in Aug 2025, 2 years 10 months after primary completion.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 22 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BMS201038
Homozygous Familial Hypercholesterolemia →